Latest News and Press Releases

วางตำแหน่ง Curium เป็นผู้ผลิตไอโซโทป Lu-177 ชั้นนำนำความเชี่ยวชาญด้านการวิจัยและพัฒนาที่เป็นนวัตกรรมและลำดับขั้นตอนการทำงานมาสู่ Curiumเพิ่มความครอบคลุมทางภูมิศาสตร์และห่วงโซ่อุปทาน SPECT & PET...

Curium, 루테튬-177 동위원소 선도적 제조업체로 자리매김Curium은 혁신적인 R&D 전문성과 파이프라인 확보 효과Curium의 SPECT 및 PET 지리적 범위와 공급망 강화 파리, March 29, 2025 (GLOBE NEWSWIRE) -- 핵의학 분야를 선도하는 Curium Pharma(이하 “Curium”)가 터키 이스탄불에...

Menempatkan Curium sebagai produsen terkemuka isotop Lu-177Memberikan keahlian Litbang dan rangkaian tahap pengembangan produk (pipeline) yang inovatif ke CuriumMeningkatkan jangkauan geografis dan...

确立了 Curium 的镥-177 同位素领先制造商地位为 Curium 注入创新的研发专业技术和产品管线拓展 Curium 的 SPECT 和 PET 地理覆盖范围和供应链 巴黎, March 29, 2025 (GLOBE NEWSWIRE) -- 全球核医学领域领导者 Curium Pharma (“Curium”) 宣布完成对 Eczacıbaşı-Monrol Nuclear...

Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium

Curium announced today that it has expanded its existing partnership with Institute of Isotopes Co. Ltd. (Izotop).

Curium announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate cancer.

ST. LOUIS, Mo., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that it has completed enrollment of its Phase 3 SOLAR-RECUR clinical trial. The trial is a...

ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center,...

*שיתוף פעולה שיכלול פיתוח קליני, הגשה רגולטורית ומסחור ביפן של 177Lu-PSMA-I&T ו- 64Cu-PSMA-I&T *מתבסס על מערכת יחסים ארוכת שנים בין שתי החברות *ביפן מאובחנים מדי שנה כ-90,000 מקרים חדשים...